TY - JOUR
T1 - Role of Experience With Preventive Medication and Personal Risk Attitude in Non-Attendance at Triple Vascular Screening
AU - Hansen, Tina B.
AU - Lindholt, Jes S.
AU - Søgaard, Rikke
PY - 2018/8
Y1 - 2018/8
N2 - BACKGROUND: Non-attendance for vascular screening potentially restricts the overall benefit of screening at population level, but may be the result of rational judgment on the part of invitees who might not consider their risk to be relevant. The aim of this study was to investigate the role of current use of preventive medication and personal risk attitude as potential factors explaining non-attendance at triple vascular screening.METHODS: This was a case control study across 25,078 men offered screening and intervention for abdominal aortic aneurysm, peripheral artery disease, and hypertension in the Viborg Vascular (VIVA) screening trial. Data on socio-demographic and socio-economic characteristics, diagnoses, and use of preventive medication were extracted from national registries. A proxy for personal risk attitude was constructed. Logistic regression was used to estimate odds ratios with 95% confidence intervals.RESULTS: Use of statins (0.78; 95% CI 0.71-0.85), antihypertensives (1.26, 95% CI 1.13-1.41), or antithrombotics (1.13, 95% CI 1.04-1.23) were all associated with non-attendance. With regards to personal risk attitude, a statistically significant association was found between users of preventive medication with no recent diagnosis of cardiovascular disease and non-attendance (0.82, 95% CI 0.72-0.94). The role of traditional factors explaining non-attendance at vascular screening, such as low socio-economic status and comorbidity, was confirmed.CONCLUSION: Non-attendance at triple vascular screening is influenced by use of preventive medications and traditional explanatory factors of non-attendance at vascular screening, including existing CVD comorbidity. Attendance rates might benefit from rethinking risk communication alongside screening invitations according to varying invitee profiles and clinical risk scenarios, and from providing interventions targeted at individuals with lower levels of health literacy.
AB - BACKGROUND: Non-attendance for vascular screening potentially restricts the overall benefit of screening at population level, but may be the result of rational judgment on the part of invitees who might not consider their risk to be relevant. The aim of this study was to investigate the role of current use of preventive medication and personal risk attitude as potential factors explaining non-attendance at triple vascular screening.METHODS: This was a case control study across 25,078 men offered screening and intervention for abdominal aortic aneurysm, peripheral artery disease, and hypertension in the Viborg Vascular (VIVA) screening trial. Data on socio-demographic and socio-economic characteristics, diagnoses, and use of preventive medication were extracted from national registries. A proxy for personal risk attitude was constructed. Logistic regression was used to estimate odds ratios with 95% confidence intervals.RESULTS: Use of statins (0.78; 95% CI 0.71-0.85), antihypertensives (1.26, 95% CI 1.13-1.41), or antithrombotics (1.13, 95% CI 1.04-1.23) were all associated with non-attendance. With regards to personal risk attitude, a statistically significant association was found between users of preventive medication with no recent diagnosis of cardiovascular disease and non-attendance (0.82, 95% CI 0.72-0.94). The role of traditional factors explaining non-attendance at vascular screening, such as low socio-economic status and comorbidity, was confirmed.CONCLUSION: Non-attendance at triple vascular screening is influenced by use of preventive medications and traditional explanatory factors of non-attendance at vascular screening, including existing CVD comorbidity. Attendance rates might benefit from rethinking risk communication alongside screening invitations according to varying invitee profiles and clinical risk scenarios, and from providing interventions targeted at individuals with lower levels of health literacy.
KW - Aortic aneurysm
KW - Hypertension
KW - Mass screening
KW - Peripheral arterial disease
KW - Secondary prevention
KW - Vascular disease
KW - Predictive Value of Tests
KW - Humans
KW - Fibrinolytic Agents/therapeutic use
KW - Male
KW - Case-Control Studies
KW - Hypertension/diagnosis
KW - Registries
KW - Odds Ratio
KW - Antihypertensive Agents/therapeutic use
KW - Primary Prevention/methods
KW - Risk Assessment
KW - Risk Factors
KW - Logistic Models
KW - Treatment Outcome
KW - Health Knowledge, Attitudes, Practice
KW - Randomized Controlled Trials as Topic
KW - Denmark/epidemiology
KW - Peripheral Arterial Disease/diagnosis
KW - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
KW - Aged
KW - Aortic Aneurysm, Abdominal/diagnostic imaging
KW - Patient Compliance
KW - Mass Screening/methods
U2 - 10.1016/j.ejvs.2018.04.016
DO - 10.1016/j.ejvs.2018.04.016
M3 - Journal article
C2 - 29891436
AN - SCOPUS:85048192330
SN - 1078-5884
VL - 56
SP - 282
EP - 290
JO - European Journal of Vascular and Endovascular Surgery
JF - European Journal of Vascular and Endovascular Surgery
IS - 2
ER -